Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.
Chao NJ, Parker PM, Niland JC, Wong RM, Dagis A, Long GD, Nademanee AP, Negrin RS, Snyder DS, Hu WW, Gould KA, Tierney DK, Zwingenberger K, Forman SJ, Blume KG. Chao NJ, et al. Among authors: negrin rs. Biol Blood Marrow Transplant. 1996 May;2(2):86-92. Biol Blood Marrow Transplant. 1996. PMID: 9118303 Clinical Trial.
Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival.
Ross M, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Forman SJ, Blume KG, Chao NJ. Ross M, et al. Among authors: negrin rs. Biol Blood Marrow Transplant. 1999;5(5):285-91. doi: 10.1016/s1083-8791(99)70003-0. Biol Blood Marrow Transplant. 1999. PMID: 10534058 Free article. Clinical Trial.
Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.
Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG, Negrin RS, Chao NJ. Johnston LJ, et al. Among authors: negrin rs. Biol Blood Marrow Transplant. 2005 Jan;11(1):47-55. doi: 10.1016/j.bbmt.2004.10.004. Biol Blood Marrow Transplant. 2005. PMID: 15625544 Free article. Clinical Trial.
CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies.
Cao TM, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Negrin RS, Lowsky R. Cao TM, et al. Among authors: negrin rs. Exp Hematol. 2005 Mar;33(3):279-85. doi: 10.1016/j.exphem.2004.12.004. Exp Hematol. 2005. PMID: 15730851 Free article.
Protective conditioning for acute graft-versus-host disease.
Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Hoppe RT, Bloch DA, Blume KG, Negrin RS, Strober S. Lowsky R, et al. Among authors: negrin rs. N Engl J Med. 2005 Sep 29;353(13):1321-31. doi: 10.1056/NEJMoa050642. N Engl J Med. 2005. PMID: 16192477 Free article. Clinical Trial.
304 results